ORG
Amgen Secures FDA Approval for Bkemv, the First Interchangeable Biosimilar to Soliris for Rare Blood Disorders
FDA approval, Amgen, Bkemv, Soliris, biosimilar, rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)
Repare Backer Amplitude Ventures Launches $192M Biotech Fund for Development and Growth
Amplitude Ventures, biotech fund, Repare Therapeutics, development, growth, investment, biotechnology
Ikena Oncology Cuts Hippo Pathway Inhibitor, Lays Off Half of Staff in Strategic Reprioritization
Ikena Oncology, Hippo pathway inhibitor, TEAD1-selective, layoffs, strategic update, biotech industry, clinical trials, cancer treatment
James Sabry Departs Roche After 14 Years, Returns to Biotech Industry
James Sabry, Roche, Genentech, Biotech, Partnering, Pharmaceutical Industry, Career Moves
Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial
Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment
Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market
Asahi Kasei, Calliditas Therapeutics, acquisition, rare disease market, kidney disease, Tarpeyo, IgA nephropathy, pharmaceutical growth strategy
Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis
Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.
BioNTech Expands ADC Alliance with MediLink, Investing $1.8 Billion
BioNTech, MediLink, ADC alliance, $1.8 billion, oligonucleotide therapy, gene therapy, molecular biology
Gilead and Cartography Collaborate to Identify Novel Antigen Targets for Cancer Therapy
Gilead Sciences, Cartography Biosciences, cancer therapy, antigen targets, triple-negative breast cancer, lung adenocarcinoma, ATLAS platform, SUMMIT platform, oncology, drug development.
Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing
Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care